Bibliography
Found 36 results
Filters: Keyword is Anti-Retroviral Agents [Clear All Filters]
Is the glass three-quarters full or one-quarter empty?. J Infect Dis. 2006 ;194(12):1628-31.
. Human immunodeficiency virus and the central nervous system. The Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases [Internet]. 2006 ;10:41-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16767315
. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology [Internet]. 2006 ;179:180-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16901548
. Dementia and neurocognitive disorders due to HIV-1 infection. Seminars in Neurology [Internet]. 2007 ;27:86-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17226745
. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (London, England) [Internet]. 2007 ;21:1877-86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17721095
White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009 ;15(2):187-95.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
A case of primary HIV type 1 and cytomegalovirus coinfection presenting with widespread clinical disease. J Int Assoc Provid AIDS Care. 2014 ;13(3):196-9.
. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS. 2014 ;28(11):1579-91.
. Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. J Neurovirol. 2014 ;20(4):371-9.
. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014 ;218(1-2):201-8.
. Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014 ;9(8):e103123.
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014 ;20(3):209-18.
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART. J Neurovirol. 2014 ;20(3):294-303.
Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS. 2015 ;29(3):323-30.
. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.
HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. J Virol. 2016 ;90(20):8968-83.
HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer. J Virol. 2016 ;90(20):8984-93.
Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One. 2016 ;11(6):e0157160.
At-Risk Alcohol Use is Associated with Antiretroviral Treatment Nonadherence Among Adults Living with HIV/AIDS. Alcohol Clin Exp Res. 2017 ;41(8):1518-1525.
.